ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Priya Kumthekar(Northwestern University), Nuhad K. Ibrahim(The University of Texas MD Anderson Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Jose Carrillo(Saint John's Health Center), Carey K. Anders(Duke Medical Center), Peter Kabos(University of Colorado Anschutz Medical Campus), Manmeet S. Ahluwalia(Baptist Hospital of Miami), David Piccioni(Center for Personalized Cancer Treatment), Santosh Kesari(Cancer Institute (WIA)), Agustin Garcia(Louisiana State University), Katherine Tkaczuk(University of Mary), Pavani Chalasani(University of Arizona), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Shou‐Ching Tang(University of Mississippi Medical Center), Shannon Puhalla(UPMC Hillman Cancer Center), Jeffrey S. Wefel(The University of Texas MD Anderson Cancer Center)
Cited by 242
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
|Neuro-Oncology|2013|942
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
|Journal of Clinical Oncology|2020|827
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766